공시 • Mar 10
SunBio,Inc., Annual General Meeting, Mar 24, 2026 SunBio,Inc., Annual General Meeting, Mar 24, 2026, at 11:00 Tokyo Standard Time. Location: conference room, 129, eunbong-ro, namdong-gu, incheon South Korea 공시 • Mar 25
SunBio,Inc. (KOSDAQ:A067370) announces an Equity Buyback for 160,513 shares, for KRW 1,000 million. SunBio,Inc. (KOSDAQ:A067370) announces a share repurchase program. Under the program, the company will repurchase up to 160, 513 shares, for KRW 1,000 million pursuant to a trust contract with Korea Investment & Securities. The shares will be repurchased at a price of KRW 6,230 per share. The purpose of the share repurchase program is to stabilize the share price and to enhance shareholder value. The share repurchase program is valid until September 25, 2025. As of March 23, 2025, the company had 8,222 shares in treasury within scope available for dividend and had no shares in treasury through other repurchase. 공시 • Mar 07
SunBio,Inc., Annual General Meeting, Mar 31, 2025 SunBio,Inc., Annual General Meeting, Mar 31, 2025, at 10:30 Tokyo Standard Time. Location: conference room, 129, eunbong-ro, namdong-gu, incheon South Korea Upcoming Dividend • Dec 20
Upcoming dividend of ₩75.00 per share Eligible shareholders must have bought the stock before 27 December 2024. Payment date: 11 April 2025. Trailing yield: 1.0%. Lower than top quartile of South Korean dividend payers (3.9%). Higher than average of industry peers (0.5%). New Risk • Nov 01
New minor risk - Dividend sustainability The company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 1.2% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2014 fiscal period end). High level of non-cash earnings (95% accrual ratio). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (₩77.9b market cap, or US$56.6m). 공시 • Sep 04
SunBio,Inc. announced that it expects to receive KRW 5 billion in funding from Samsung Securities Co.,Ltd., NH Investment & Securities Co., Ltd., Mirae Asset Securities Co., Ltd. and another investor SunBio,Inc. announced a private placement to issue Zero Coupon Series 4 Bearer-Type Interest-Free Unsecured Private Placement Convertible Bonds due September 5, 2029 for the gross proceeds of KRW 5,000,000,000 on September 3, 2024. The transaction will include participation from new investors Synergy IB Win-Win Innovation New Technology Investment Fund KRW 2,500,000,000,Samsung Securities Co., Ltd. (in the fiduciary position of Fund 1) KRW 1,200,000,000, NH Investment & Securities Co., Ltd . (in the fiduciary position of Fund 2) KRW 800,000,000 and Mirae Asset Securities Co., Ltd. (in the fiduciary position of Fund 3) KRW 500,000,000. The transaction has been approved by shareholders, restricted to a hold period and is expected to close on September 5, 2024. The bonds are 100% convertible into 676,315 shares at a fixed conversion price of KRW 7,393 from September 5, 2025 to August 5, 2029. The bonds bear zero coupon and maturity rate and matures on September 5, 2029. 공시 • Mar 10
SunBio,Inc., Annual General Meeting, Mar 29, 2021 SunBio,Inc., Annual General Meeting, Mar 29, 2021, at 11:00 Korea Standard Time. Is New 90 Day High Low • Feb 15
New 90-day high: ₩22,000 The company is up 140% from its price of ₩9,167 on 17 November 2020. The South Korean market is up 21% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 9.0% over the same period. Is New 90 Day High Low • Dec 16
New 90-day high: ₩17,950 The company is up 2.0% from its price of ₩17,650 on 17 September 2020. The South Korean market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 5.0% over the same period. Is New 90 Day High Low • Nov 19
New 90-day low: ₩13,450 The company is down 4.0% from its price of ₩13,950 on 21 August 2020. The South Korean market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period.